Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals

Although sorafenib is currently used as a standard treatment for advanced hepatocellular carcinoma, low response rate, transient and limited efficacy, primary and acquired resistance and negative side-effects gain increasing attentions, suggesting the need for better efficacious combination therapy....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Death Dis
Autori principali: Xu, Junjie, Zheng, Longbo, Chen, Jiang, Sun, Yin, Lin, Hui, Jin, Ren-an, Tang, Minyue, Liang, Xiao, Cai, Xiujun
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2017
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5680567/
https://ncbi.nlm.nih.gov/pubmed/29022906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2017.411
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi